IP Verse

Use Of Eicosapentaenoic Acid Ethyl Ester For Treating Hypertriglyceridemia - EP2596786

The patent EP2596786 was granted to Amarin Pharmaceuticals Ireland on Nov 27, 2019. The application was originally filed on Feb 9, 2010 under application number EP13156122A. The patent is currently recorded with a legal status of "Revoked".

EP2596786

AMARIN PHARMACEUTICALS IRELAND
Application Number
EP13156122A
Filing Date
Feb 9, 2010
Status
Revoked
Oct 7, 2022
Grant Date
Nov 27, 2019
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

HOFFMANN EITLEAug 26, 2020HOFFMANN EITLEADMISSIBLE
ELKINGTON AND FIFEAug 25, 2020ELKINGTON AND FIFEADMISSIBLE

Patent Citations (7) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
OPPOSITIONEP0610506
OPPOSITIONEP1790338
OPPOSITIONEP1790339
OPPOSITIONEP2395991
OPPOSITIONUS2008200547
OPPOSITIONWO2010028067
OPPOSITIONWO2010093634

Non-Patent Literature (NPL) Citations (67) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- BURTIS, ASHWOOD AND BORTER, Tietz Fundamentals of Clinical Chemistry, 6th Ed., WB SAUNDERS COMPANY-
EXAMINATION- ANONYMOUS, "Epadel Capsules 300 - Drug information brochure (in Japanese)", MOCHIDA PHARMACEUTICAL CO., LTD, (200001), pages 1 - 16, XP055260399-
EXAMINATION- ANONYMOUS, "Epadel Capsules 300 (English translation of Japanese drug information brochure)", MOCHIDA PHARMACEUTICAL CO., LTD, (200001), pages 1 - 20, XP055260418-
EXAMINATION- Anonymous, "LOVAZA TM (omega-3-acid ethyl esters) Capsules", internet, (200708), pages 1 - 2, URL: https://www.accessdata.fda.gov/drugsatfda_docs/label/2008/021654s021lblR.pdf, (20190516), XP055589332-
EXAMINATION- NISHIKAWA MASAZUMI ET AL, "Effects of eicosapentaenoic acid (EPA) on prostacyclin production in diabetics: GC/MS analysis of PGI2 and PGI3 levels", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY., (199707), vol. 19, no. 6, ISSN 0379-0355, pages 429 - 433, XP055393737-
EXAMINATION- KURABAYASHI TAKUMI ET AL, "Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women", OBSTETRICS AND GYNECOLOGY, US, (200010), vol. 96, no. 4, doi:10.1016/S0029-7844(00)00988-1, ISSN 0029-7844, pages 521 - 528, XP055393453
EXAMINATION- NASA YOSHIHISA ET AL, "Long-term supplementation with eicosapentaenoic acid salvages cardiomyocytes from hypoxia/reoxygenation-induced injury in rats fed with fish-oil-deprived diet", JAPANESE JOURNAL OF PHARMACOLOGY., KYOTO, JP, (199806), vol. 77, no. 2, ISSN 0021-5198, pages 137 - 146, XP055393449
EXAMINATION- SHINOZAKI KOJI ET AL, "The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein (a) and lipids in patients with vascular disease", JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, JP, (199601), vol. 2, no. 2, ISSN 1340-3478, pages 107 - 109, XP055393438
OPPOSITION- "Amarin Appoints Medpace as CRO for two Phase 3 Cardiovascular Trials", AMARIN PRESS RELEASE, Dublin, Irland, (19-10-2009), pages 1 - 2-
OPPOSITION- "Amarin Corporation Announces First Patients Enrolled in two Phase 3 Clinical Trials Assessing AMR101 for the Treatment of cardiovascular Disease - Lowering Triglyceride Levels for at-risk patient -s", AMARIN press release, San Francisco, USA, (11-01-2010), pages 1 - 2-
OPPOSITION- "AMARIN CORP PLC\UK - 20-F", Amarin Information Sheet, (20100000), XP055753755-
OPPOSITION- Amarin information sheet 2010, pages 1 - 21-
OPPOSITION- "Amarin Proceeding To Phase 3 With AMR101 For Hypertriglyceridemia", (23-07-2008)-
OPPOSITION- Anonymous, "Next generation lipid modification in cardiovascular disease", Amarin, (20100301), pages 1 - 25, Amarin, (20201125), XP055753751-
OPPOSITION- Declan doogan MD et al, "can omega 3 fatty acid(s) be considered medicine?", Amarin Presentation, (20080000), XP055753753-
OPPOSITION- "Epadel Capsules 300 Drug information brochure", Mochida Pharmaceutical, (2000), XP055260399-
OPPOSITION- Epadel Capsules clinical data pages 1 - 20-
OPPOSITION- "EPADELS300 EPADEL S600 EPADEL S900", Standard Industrial Classification for Japan, (2007-01), XP055753769-
OPPOSITION- Harris W S, H N Ginsberg, N Arunakul, N S Shachter, S L Windsor, M Adams, L Berglund, K Osmundsen, "Safety and efficacy of Omacor in severe hypertriglyceridemia", JOURNAL OF CARDIOVASCULAR RISK, US, (19970929), vol. 4, ISSN 1350-6277, pages 385 - 391, XP055828751-
OPPOSITION- Hata Yoshiya, N. Hirose; Y. Mizuno; K. Funatsu; M. Kato; K. Noya; H. Ookawa; Y. Kiryu; M. Yasuda; T. Hagiwara; N. Hattori; T. Mizuno, "Examination of Clinical Usefulness of Ethyl Icosapentate (EPA-E, MND-21) For Its Long-term Administration Against Hyperlipidemia", Geriatric Medicine, (19920101), vol. 30, no. 5, pages 799 - 818, XP055828587-
OPPOSITION- Kawasaki Jiro, Ministry Of Health, Labour And Welfare, "The Japanese Pharmacopoeia 16th Edition", (20070423), pages 646 - 647, XP055828502-
OPPOSITION- Lovaza drug information 2007-
OPPOSITION- Lovaza drug information 2008-
OPPOSITION- "LOVAZA® (omega-3-acid ethyl esters)Capsules", GSK Prescribing Information, (20080000), XP055753758-
OPPOSITION- "Lovaza product information", Leaflet, (20070000), XP055753756-
OPPOSITION- Masazumi Nishikawa, Hishinuma T; Nagata K; Koseki Y; Suzuki K; Mizugaki M, "Effects of eicosapentaenoic acid (EPA) on prostacyclin production in diabetics: GC/MS analysis of PGI2 and PGI3 levels", METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY., (19970701), vol. 19, no. 6, ISSN 0379-0355, pages 429 - 433, XP055393737-
OPPOSITION- Mochida Announces Completion of "JELIS" Major Clinical Trial for Epadel Hyperlipidemia and Arteriosclerosis Obliterans Therapeutic Treatment; March 2005; pages 2 - 8-
OPPOSITION- MORI et al., "Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men", Am J Clin Nutr, (20000000), vol. 71, no. 5, pages 1085 - 94, XP002410552-
OPPOSITION- MORI T A ET AL, "Purified eicosapentaenoic and docosahexaenoic acids have differential effects on serum lipids and lipoproteins, LDL particle size, glucose, and insulin in mildly hyperlipidemic men.", American Journal of Clinical Nutrition, (20000501), vol. 71, no. 5, ISSN 0002-9165, pages 1085 - 1094, XP002410552-
OPPOSITION- "Next generation lipid modification in cardiovascular disease", Amarin Presentation, (20100000), XP055753751-
OPPOSITION- "Next Generation Lipid Modification in Cardiovascular Disease", AMARIN TM-
OPPOSITION- Nozaki S; Matsuzawa Y; Hirano K; Sakai N; Kubo M; Tarui S, "Effects of purified eicosapentaenoic acid ethyl ester on plasma lipoproteins in primary hypercholesterolemia", INTERNATIONAL JOURNAL FOR VITAMIN & NUTRITION RESEARCH, CH, (19920101), vol. 62, no. 3, ISSN 0300-9831, pages 256 - 260, XP009132430-
OPPOSITION- "O3 GYN News"-
OPPOSITION- OH ROBERT C ET AL, "Management of hypertriglyceridemia.", AMERICAN FAMILY PHYSICIAN, American Academy of Family Physicians, US, US, (20070501), vol. 75, no. 9, ISSN 0002-838X, pages 1365 - 1371, XP002578781-
OPPOSITION- Recommendation for lipid plasma levels-
OPPOSITION- Richter Werner O., Windach, "Hypertriglyceridamie", (20160420), pages 1 - 35, 48, XP055828476-
OPPOSITION- Sameline Grimsgaard, "Highly purified eicosapentaenoic acid and docosahexaenoic acid in humans have similar triacylglycerol-lowering effects but divergent effects on serum fatty acids", Am J Clin Nutr 1997;66, (19970418), vol. 66, pages 649 - 659, XP055069546-
OPPOSITION- SATO M. ET AL., "Effects of Highly Purified Ethyl All-cis-5,8-11,14,17-icosapentaenoate (EPA-E) on Rabbit Platelets", BIOLOGICAL & PHARMACEUTICAL BULLETIN, (19930101), vol. 16, no. 4, pages 362 - 367, XP008116207-
OPPOSITION- VON SCHACKY CLEMENS, "A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels.", VASCULAR HEALTH AND RISK MANAGEMENT, DOVE MEDICAL PRESS LTD.,, NZ, NZ, (20060101), vol. 2, no. 3, ISSN 1176-6344, pages 251 - 262, XP002578779-
OPPOSITION- NAKAMURA N ET AL, "Joint effects of HMG-CoA reductase inhibitors and eicosapentaenoic acids on serum lipid profile and plasma fatty acid concentrations in patients with hyperlipidemia.", INTERNATIONAL JOURNAL OF CLINICAL AND LABORATORY RESEARCH., SPRINGER, BERLIN, DE, (19990301), vol. 29, no. 1, doi:10.1007/s005990050057, ISSN 0940-5437, pages 22 - 25, XP002558875
OPPOSITION- Wojenski, C.M. ; Silver, M.J. ; Walker, J., "Eicosapentaenoic acid ethyl ester as an antithrombotic agent: comparison to an extract of fish oil", BIOCHIMICA ET BIOPHYSICA ACTA - LIPIDS AND LIPID METABOLISM., ELSEVIER SCIENCE BV., NL, (19910104), vol. 1081, no. 1, doi:10.1016/0005-2760(91)90246-E, ISSN 0005-2760, pages 33 - 38, XP023578091
OPPOSITION- HAYASHI et al., "Decreases In Plasma Lipid Content And Thrombotic Activity By Ethyl Eicosapentate Purified From Fish Oils", Current Therapeutic Research, (19950000), vol. 56, no. 1, pages 24 - 31, XP002578780
OPPOSITION- HAYASHI KOZO ET AL, "Deceases In Plasma Lipid Content And Thrombotic Activity By Ethyl Eicosapentate Purified From Fish Oils", CURRENT THERAPEUTIC RESEARCH, EXCERPTA MEDICA, TRENTON, NJ, US, US, (19950101), vol. 56, no. 1, doi:10.1016/0011-393X(95)85016-3, ISSN 0011-393X, pages 24 - 31, XP002578780
OPPOSITION- Yukichi Okuda, Masakazu Mizutani, Masashi Ogawa, Hirohito Sone, Michiko Asano, Yukari Asakura, Masaaki Isaka, Seiji Suzuki, Yasushi Kawakami, James B. Field, Kamejiro Yamashita, "Long-term effects of eicosapentaenoic acid on diabetic peripheral neuropathy and serum lipids in patients with type II diabetes mellitus", JOURNAL OF DIABETES AND ITS COMPLICATIONS, ELSEVIER SCIENCE, NEW YORK, NY, US, (19960901), vol. 10, no. 5, doi:10.1016/1056-8727(95)00081-X, ISSN 1056-8727, pages 280 - 287, XP055393380
OPPOSITION- Harold E. Bays; Christie M. Ballantyne; John J. Kastelein; Jonathan L. Isaacsohn; Rene A. Braeckman; Paresh N. Soni;, "Eicosapentaenoic Acid Ethyl Ester (AMR101) Therapy in Patients With Very High Triglyceride Levels (from the Multi-center, plAcebo-controlled, Randomized, double-blINd, 12-week study with an open-label Extension [MARINE] Trial)", AMERICAN JOURNAL OF CARDIOLOGY., NEWTON, MA,, US, (20110424), vol. 108, no. 5, doi:10.1016/j.amjcard.2011.04.015, ISSN 0002-9149, pages 682 - 690, XP028262633
OPPOSITION- YOKOYAMA M, ET AL., "Effects of eicosaphentaenoic acid on cardiovascular events in Japanese patients with hypercholesterolemia: rationale, design, and baseline characteristics of the Japan EPA Lipid Intervention Study (JELIS)", American Heart Journal, ELSEVIER, AMSTERDAM, NL, (20030101), vol. 146, no. 4, doi:10.1016/S0002-8703(03)00367-3, ISSN 0002-8703, pages 613 - 620, XP003020148
OPPOSITION- Mizuguchi Kiyoshi, T. Yano; M. Kojima; Y.Tanaka; M. Ishibashi; A. Masada; M. Sato; M. Mizota; K. Fukutake; Y. Saito, "Hypolipidemic Effect of Ethyl all-cis-5,8,11,14,17-Icosapentaenoate (EPA-E) in Rats", Japanese Journal of Pharmacology, (19920101), vol. 59, no. 3, doi:10.1016/S0021-5198(19)37627-9, pages 307 - 312, XP055828964
OPPOSITION- Pownall Henry J, Brauchi Danièle, Kilinç Cumhur, Osmundsen Karin, Pao Quein, Payton-Ross Charlotte, Gotto Antonio M, Ballantyne Christie M, "Correlation of serum triglyceride and its reduction by ω-3 fatty acids with lipid transfer activity and the neutral lipid compositions of high-density and low-density lipoproteins", Atherosclerosis, ELSEVIER, AMSTERDAM, NL, (19990401), vol. 143, no. 2, doi:10.1016/S0021-9150(98)00301-3, ISSN 0021-9150, pages 285 - 297, XP055828958
OPPOSITION- KURUBAYASHI et al., "Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women", Obstet Gynecol, (20000000), vol. 96, no. 4, pages 521 - 8, XP055393453
OPPOSITION- Takumi Kurabayashi, Okada Masahiko, Tanaka Kenichi, "Eicosapentaenoic acid effect on hyperlipidemia in menopausal Japanese women", Obstetrics and Gynecology, Lippincott Williams & Wilkins, US, US, (20001001), vol. 96, no. 4, doi:10.1016/S0029-7844(00)00988-1, ISSN 0029-7844, pages 521 - 528, XP055393453
OPPOSITION- Yokoyama, M. Origasa, H. Matsuzaki, M. Matsuzawa, Y. Saito, Y. Ishikawa, Y. Oikawa, S. Sasaki, J. Hishida, H. Itakura, H. Kita, T. Kitabatake, A. Nakaya, N. Sakata, T. Shimada, K. Shirato, K., "Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis", The Lancet, ELSEVIER, AMSTERDAM, NL, (20070330), vol. 369, no. 9567, doi:10.1016/S0140-6736(07)60527-3, ISSN 0140-6736, pages 1090 - 1098, XP022009572
OPPOSITION- Martz Lauren, Writer Staff, "Moving upstream in Huntington's", Science-Business eXchange, (20081001), vol. 1, no. 35, doi:10.1038/scibx.2008.841, page 1, XP055828963
OPPOSITION- Okumura Takahiro, Y. Fujioka; S. Morimoto; S. Tsuboi; M. Masai; T. Tsujino; M. Ohyanagi; T. Iwasaki, "Eicosapentaenoic Acid Improves Endothelial Function in Hypertriglyceridemic Subjects Despite Increased Lipid Oxidizability", (20021101), vol. 324, no. 5, doi:10.1097/00000441-200211000-00003, pages 247 - 253, XP055828396
OPPOSITION- Mori Trevor A, Woodman Richard J, "The independent effects of eicosapentaenoic acid and docosahexaenoic acid on cardiovascular risk factors in humans", CURRENT OPINION IN CLINICAL NUTRITION AND METABOLIC CARE, Lippincott Williams & Wilkins, US, (20060301), vol. 9, no. 2, doi:10.1097/01.mco.0000214566.67439.58, ISSN 1363-1950, pages 95 - 104, XP055828598
OPPOSITION- Itoh Michiko, Suganami Takayoshi, Satoh Noriko, Tanimoto-Koyama Kanami, Yuan Xunmei, Tanaka Miyako, Kawano Hiroyuki, Yano Takashi, Aoe Seiichiro, Takeya Motohiro, Shimatsu Akira, Kuzuya Hideshi, Kamei Yasutomi, Ogawa Yoshihiro, "Increased Adiponectin Secretion by Highly Purified Eicosapentaenoic Acid in Rodent Models of Obesity and Human Obese Subjects", Translational Sciences, Lippincott, Williams & Wilkins, (20070901), vol. 27, no. 9, doi:10.1161/ATVBAHA.106.136853, ISSN 1079-5642, pages 1918 - 1925, XP055828585
OPPOSITION- Yorioka N., T Masaki, T Ito, S. Kushihata, Y. Nishida, Y. Taniguchi, H. Oda, M. Yamakido, "Lipid-lowering therapy and coagulation/fibrinolysis parameters in patients on peritoneal dialysis", Artificial Kidney and Dialysis, (20000218), vol. 23, no. 1, doi:10.1177/039139880002300105, pages 27 - 32, XP055828373
OPPOSITION- Yoshihisa Nasa, Hayashi Michihiko; Sasaki Hideo; Hayashi Jyun-Ichi; Takeo Satoshi, "Long-term supplementation with eicosapentaenoic acid salvages cardiomyocytes from hypoxia/reoxygenation-induced injury in rats fed with fish-oil-deprived diet", JAPANESE JOURNAL OF PHARMACOLOGY., THE JAPANESE PHARMACOLOGICAL SOCIETY, KYOTO, JP, (19980601), vol. 77, no. 2, doi:10.1254/jjp.77.137, ISSN 0021-5198, pages 137 - 146, XP055393449
OPPOSITION- Bays H E, Tighe A P, Sadovsky R, Davidson M H, "Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications", EXPERT REVIEW OF CARDIOVASCULAR THERAPY, FUTURE DRUGS, LONDON, GB, (20080301), vol. 6, no. 3, doi:10.1586/14779072.6.3.391, ISSN 1477-9072, pages 391 - 409, XP002695481
OPPOSITION- McKenney J M; Sica D, "Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia", Pharmacotherapy, Wiley-Blackwell, US, (20070101), vol. 27, no. 5, doi:10.1592/phco.27.5.715, ISSN 0277-0008, pages 715 - 728, XP008115778
OPPOSITION- SHINOZAKI et al., "The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein (a) and lipids in patients with vascular disease", J Atheroscler Thromb, (19960000), vol. 2, no. 2, doi:10.5551/jat1994.2.107, pages 107 - 9, XP055393438
OPPOSITION- Shinozaki K, Kambayashi J; Kawasaki T; Uemura Y; Sakon M; Shiba E; Shibuya T; Nakamura T; Mori T, "The long-term effect of eicosapentaenoic acid on serum levels of lipoprotein (a) and lipids in patients with vascular disease", JOURNAL OF ATHEROSCLEROSIS AND THROMBOSIS, Tokyo, JP, (19960101), vol. 2, no. 2, doi:10.5551/jat1994.2.107, ISSN 1340-3478, pages 107 - 109, XP055393438
SEARCH- OH ROBERT C ET AL, "Management of hypertriglyceridemia.", AMERICAN FAMILY PHYSICIAN 1 MAY 2007 LNKD- PUBMED:17508532, (20070501), vol. 75, no. 9, ISSN 0002-838X, pages 1365 - 1371, XP002578781 [A] 1-14 * abstract * * page 1369, column 2, paragraph 2 - page 1370, column 1, paragraph 1 * * table 2 *-
SEARCH- VON SCHACKY CLEMENS, "A review of omega-3 ethyl esters for cardiovascular prevention and treatment of increased blood triglyceride levels.", VASCULAR HEALTH AND RISK MANAGEMENT 2006 LNKD- PUBMED:17326331, (2006), vol. 2, no. 3, ISSN 1176-6344, pages 251 - 262, XP002578779 [Y] 1-14 * abstract * * page 253, column 2, paragraph 3 - page 254, column 1, paragraph 2 *-
SEARCH- RAMBJOR G S ET AL, "Eicosapentaenoic acid is primarily responsible for hypotriglyceridemic effect of fish oil in humans.", LIPIDS MAR 1996 LNKD- PUBMED:8729093, (199603), vol. 31 Suppl, ISSN 0024-4201, pages S45 - S49, XP000614874 [A] 1-14 * abstract * * table 3 *
SEARCH- HAYASHI KOZO ET AL, "Deceases In Plasma Lipid Content And Thrombotic Activity By Ethyl Eicosapentate Purified From Fish Oils", CURRENT THERAPEUTIC RESEARCH, (1995), vol. 56, no. 1, ISSN 0011-393X, pages 24 - 31, XP002578780 [Y] 1-14 * abstract * * page 25, paragraph 3 * * table I *
SEARCH- BAYS H E ET AL, "Prescription omega-3 fatty acids and their lipid effects: Physiologic mechanisms of action and clinical implications", EXPERT REVIEW OF CARDIOVASCULAR THERAPY 200803 GB, (200803), vol. 6, no. 3, ISSN 1477-9072, pages 391 - 409, XP002695481 [Y] 1-14 * abstract * * tables 1,3 * * figure 4 *
SEARCH- MCKENNEY JAMES M ET AL, "Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.", PHARMACOTHERAPY MAY 2007 LNKD- PUBMED:17461707, (200705), vol. 27, no. 5, ISSN 0277-0008, pages 715 - 728, XP008115778 [Y] 1-14 * abstract * * page 719, column 1, paragraph 3 * * page 721, column 1, paragraph 2 - page 722, column 1, paragraph 2 * * tables 1-3 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents